Free Trial
→ Trump’s treachery (From Porter & Company) (Ad) Buy CLBT Stock  Free CLBT Stock Alerts

Cellebrite DI (CLBT) Financials

Cellebrite DI logo
$16.89 -0.16 (-0.94%)
Closing price 04:00 PM Eastern
Extended Trading
$17.35 +0.46 (+2.72%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Cellebrite DI

Annual Income Statements for Cellebrite DI

This table shows Cellebrite DI's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Net Income / (Loss) Attributable to Common Shareholders		 -283 -81 121 71 5.78 -1.88
Consolidated Net Income / (Loss)		 -283 -81 121 71 5.78 -1.88
Net Income / (Loss) Continuing Operations		 -283 -81 121 71 5.78 -1.88
Total Pre-Tax Income 		-276 -76 121 82 11 1.42
Total Operating Income		 57 33 1.04 14 9.22 -1.52
Total Gross Profit		 339 272 220 204 157 136
Total Revenue		 401 325 271 246 195 172
Operating Revenue		 401 325 271 246 195 172
Total Cost of Revenue		 63 53 51 43 38 36
Operating Cost of Revenue		 63 53 51 43 38 36
Total Operating Expenses		 282 239 219 190 148 138
Selling, General & Admin Expense		 51 43 41 48 32 29
Marketing Expense		 132 111 97 76 61 62
Research & Development Expense		 98 84 81 66 54 47
Total Other Income / (Expense), net		 -333 -109 120 68 2.18 2.94
Other Income / (Expense), net		 -333 -109 120 68 2.18 2.94
Income Tax Expense		 7.02 5.54 -0.05 11 5.62 3.29
Basic Earnings per Share		 ($1.35) ($0.43) $0.64 $0.49 ($0.08) ($0.08)
Weighted Average Basic Shares Outstanding		 209.47M 190.15M 182.69M 144.00M 123.70M 121.56M
Diluted Earnings per Share		 ($1.35) ($0.43) $0.59 $0.44 ($0.08) ($0.08)
Weighted Average Diluted Shares Outstanding		 209.47M 190.15M 195.39M 161.54M 123.70M 121.56M
Weighted Average Basic & Diluted Shares Outstanding		 239.47M - 205.30M 188.54M - -

Quarterly Income Statements for Cellebrite DI

No quarterly income statements for Cellebrite DI are available.

Annual Cash Flow Statements for Cellebrite DI

This table details how cash moves in and out of Cellebrite DI's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Net Change in Cash & Equivalents		 3.35 101 -57 13 51 45
Net Cash From Operating Activities		 132 102 21 36 67 16
Net Cash From Continuing Operating Activities		 132 102 21 36 67 16
Net Income / (Loss) Continuing Operations		 -283 -81 121 71 5.78 -1.88
Consolidated Net Income / (Loss)		 -283 -81 121 71 5.78 -1.88
Depreciation Expense		 11 10 9.19 7.01 5.88 4.08
Amortization Expense		 -2.90 -1.11 -0.37 0.00 0.00 -
Non-Cash Adjustments To Reconcile Net Income		 370 131 -105 -61 7.96 13
Changes in Operating Assets and Liabilities, net		 38 43 -3.92 19 47 1.17
Net Cash From Investing Activities		 -149 -23 -91 45 -6.45 -47
Net Cash From Continuing Investing Activities		 -149 -23 -91 45 -6.45 -47
Purchase of Property, Plant & Equipment		 -8.57 -5.23 -6.90 -5.11 -6.18 -6.21
Acquisitions		 -4.79 -2.69 -2.19 -23 -15 0.00
Purchase of Investments		 -335 -144 -165 -21 -139 -41
Sale and/or Maturity of Investments		 199 130 83 94 153 -
Net Cash From Financing Activities		 21 22 14 -68 -8.59 76
Net Cash From Continuing Financing Activities		 21 22 14 -68 -8.59 76
Issuance of Common Equity		 3.34 2.62 1.34 0.00 0.00 -
Other Financing Activities, net		 17 19 13 32 1.49 0.14
Cash Income Taxes Paid		 7.71 10 9.05 8.16 2.91 3.00

Quarterly Cash Flow Statements for Cellebrite DI

No quarterly cash flow statements for Cellebrite DI are available.

Annual Balance Sheets for Cellebrite DI

This table presents Cellebrite DI's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Total Assets		 691 533 403 340 364
Total Current Assets		 568 422 296 273 324
Cash & Equivalents		 192 190 88 146 129
Short-Term Investments		 102 39 45 0.00 -
Accounts Receivable		 82 77 79 68 66
Inventories, net		 8.94 9.94 10 6.51 4.75
Prepaid Expenses		 23 26 17 13 7.44
Other Current Assets		 160 80 58 40 112
Plant, Property, & Equipment, net		 17 16 17 17 16
Total Noncurrent Assets		 106 95 90 50 24
Long-Term Investments		 37 29 22 0.00 -
Goodwill		 29 27 27 27 9.46
Intangible Assets		 11 11 11 11 6.61
Noncurrent Deferred & Refundable Income Taxes		 11 7.02 13 9.80 7.37
Other Noncurrent Operating Assets		 18 22 17 1.96 0.57
Total Liabilities & Shareholders' Equity		 691 533 403 340 364
Total Liabilities		 355 499 329 413 199
Total Current Liabilities		 296 254 208 187 159
Accounts Payable		 74 53 50 64 54
Current Deferred Revenue		 217 196 153 123 106
Other Current Liabilities		 4.13 4.97 5.00 0.00 -
Total Noncurrent Liabilities		 59 245 122 227 40
Noncurrent Deferred Revenue		 45 47 42 36 33
Other Noncurrent Operating Liabilities		 14 198 79 190 6.19
Commitments & Contingencies		 0.00 0.00 0.00 0.00 -
Total Equity & Noncontrolling Interests		 336 34 74 -73 64
Total Preferred & Common Equity		 336 34 74 -73 64
Total Common Equity		 336 34 74 -73 64
Common Stock		 499 -85 -126 -153 34
Retained Earnings		 -165 118 199 78 28
Treasury Stock		 -0.09 -0.09 -0.09 -0.09 -0.09
Accumulated Other Comprehensive Income / (Loss)		 2.09 1.05 0.33 1.37 1.32

Quarterly Balance Sheets for Cellebrite DI

No quarterly balance sheets for Cellebrite DI are available.

Annual Metrics And Ratios for Cellebrite DI

This table displays calculated financial ratios and metrics derived from Cellebrite DI's official financial filings.

Metric 2024 2023 2022 2021 2020 2019
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Growth Metrics		 - - - - - -
Revenue Growth		 23.41% 20.12% 9.91% 26.34% 13.42% 0.00%
EBITDA Growth		 -302.47% -151.44% 45.09% 416.97% 214.45% 0.00%
EBIT Growth		 -265.24% -162.57% 46.72% 622.16% 705.44% 0.00%
NOPAT Growth		 71.21% 2,127.70% -91.29% 156.43% 132.02% 0.00%
Net Income Growth		 -248.96% -167.13% 69.20% 1,135.01% 408.16% 0.00%
EPS Growth		 -213.95% -172.88% 34.09% 650.00% 0.00% 0.00%
Operating Cash Flow Growth		 29.51% 395.98% -42.92% -45.79% 312.26% 0.00%
Free Cash Flow Firm Growth		 -214.13% 220.22% -152.47% 1,090.94% 0.00% 0.00%
Invested Capital Growth		 102.67% -176.68% 63.27% -803.78% 0.00% 0.00%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - -
Gross Margin		 84.40% 83.63% 81.25% 82.72% 80.57% 79.16%
EBITDA Margin		 -66.87% -20.50% 47.88% 36.27% 8.86% 3.20%
Operating Margin		 14.18% 10.22% 0.39% 5.61% 4.73% -0.88%
EBIT Margin		 -68.79% -23.24% 44.62% 33.42% 5.85% 0.82%
Profit (Net Income) Margin		 -70.54% -24.95% 44.64% 28.99% 2.97% -1.09%
Tax Burden Percent		 102.54% 107.33% 100.04% 86.75% 50.72% -132.58%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% -0.04% 13.25% 49.28% 232.58%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 30.01% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 28.36% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% -23.00% 0.00%
Return on Equity (ROE)		 -152.88% -150.08% 46,642.86% 155.78% 7.01% 0.00%
Cash Return on Invested Capital (CROIC)		 -3,180.15% 0.00% 0.00% 0.00% -169.99% 0.00%
Operating Return on Assets (OROA)		 -45.12% -16.14% 32.50% 23.38% 3.13% 0.00%
Return on Assets (ROA)		 -46.26% -17.33% 32.51% 20.28% 1.59% 0.00%
Return on Common Equity (ROCE)		 -152.88% -150.08% 46,642.86% -16.22% 2.71% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 -84.22% -237.05% 163.55% -97.34% 9.06% 0.00%
Net Operating Profit after Tax (NOPAT)		 40 23 1.04 12 4.68 2.02
NOPAT Margin		 9.93% 7.16% 0.39% 4.87% 2.40% 1.17%
Net Nonoperating Expense Percent (NNEP)		 -109.97% -50.73% 79.74% 42.46% 1.65% 0.00%
Return On Investment Capital (ROIC_SIMPLE)		 11.85% 68.01% 1.41% - - -
Cost of Revenue to Revenue		 15.60% 16.37% 18.75% 17.28% 19.43% 20.85%
SG&A Expenses to Revenue		 12.69% 13.36% 15.09% 19.47% 16.49% 17.09%
R&D to Revenue		 24.53% 25.96% 29.79% 26.62% 27.90% 27.10%
Operating Expenses to Revenue		 70.21% 73.40% 80.86% 77.10% 75.84% 80.04%
Earnings before Interest and Taxes (EBIT)		 -276 -76 121 82 11 1.42
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -268 -67 130 89 17 5.49
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 13.46 49.28 11.13 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 15.28 0.00 22.97 0.00 0.00 0.00
Price to Revenue (P/Rev)		 11.27 5.19 3.04 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 6.80 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 14.70% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 705.59 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 10.45 4.40 2.47 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 5.15 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 5.53 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 105.25 61.42 639.25 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 31.72 14.00 32.45 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 8.63 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.59 -3.81 -579.90 -3.05 -0.81 0.00
Leverage Ratio		 3.30 8.66 1,434.51 7.68 2.21 0.00
Compound Leverage Factor		 3.30 8.66 1,434.51 7.68 2.21 0.00
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 61.33% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 38.67% 0.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 7.05 2.86 4.11 0.00 0.00 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 110.41% 61.33% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 1.92 1.66 1.42 1.46 2.03 0.00
Quick Ratio		 1.27 1.20 1.02 1.14 1.22 0.00
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 -189 166 -138 262 -26 0.00
Operating Cash Flow to CapEx		 1,542.97% 1,951.02% 298.35% 705.38% 1,076.04% 259.83%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.66 0.69 0.73 0.70 0.53 0.00
Accounts Receivable Turnover		 5.03 4.17 3.70 3.68 2.94 0.00
Inventory Turnover		 6.63 5.29 6.08 7.56 7.97 0.00
Fixed Asset Turnover		 24.40 19.61 15.91 14.99 12.10 0.00
Accounts Payable Turnover		 0.98 1.03 0.89 0.72 0.70 0.00
Days Sales Outstanding (DSO)		 72.61 87.59 98.63 99.18 124.20 0.00
Days Inventory Outstanding (DIO)		 55.04 68.97 60.01 48.31 45.81 0.00
Days Payable Outstanding (DPO)		 371.85 353.79 408.74 503.58 518.79 0.00
Cash Conversion Cycle (CCC)		 -244.19 -197.24 -250.10 -356.09 -348.78 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 5.94 -223 -81 -219 31 0.00
Invested Capital Turnover		 -3.70 -2.14 -1.81 -2.62 12.51 0.00
Increase / (Decrease) in Invested Capital		 229 -142 139 -250 31 0.00
Enterprise Value (EV)		 4,193 1,429 668 0.00 0.00 0.00
Market Capitalization		 4,523 1,686 822 0.00 0.00 0.00
Book Value per Share		 $1.60 $0.18 $0.39 ($0.51) $0.52 $0.00
Tangible Book Value per Share		 $1.41 ($0.02) $0.19 ($0.77) $0.39 $0.00
Total Capital		 336 34 74 -73 165 0.00
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -330 -257 -154 -146 -134 0.00
Capital Expenditures (CapEx)		 8.57 5.23 6.90 5.11 6.18 6.21
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -21 -60 -44 -59 31 0.00
Debt-free Net Working Capital (DFNWC)		 272 168 88 87 165 0.00
Net Working Capital (NWC)		 272 168 88 87 165 0.00
Net Nonoperating Expense (NNE)		 323 104 -120 -59 -1.11 3.89
Net Nonoperating Obligations (NNO)		 -330 -257 -154 -146 -134 0.00
Total Depreciation and Amortization (D&A)		 7.70 8.91 8.82 7.01 5.88 4.08
Debt-free, Cash-free Net Working Capital to Revenue		 -5.33% -18.44% -16.31% -24.10% 15.93% 0.00%
Debt-free Net Working Capital to Revenue		 67.82% 51.75% 32.57% 35.18% 84.60% 0.00%
Net Working Capital to Revenue		 67.82% 51.75% 32.57% 35.18% 84.60% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 ($1.35) $0.00 $0.00 $0.49 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 209.47M 0.00 0.00 144.00M 0.00 0.00
Adjusted Diluted Earnings per Share		 ($1.35) $0.00 $0.00 $0.44 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 209.47M 0.00 0.00 161.54M 0.00 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 239.47M 0.00 0.00 188.54M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 40 23 0.73 12 4.68 -1.06
Normalized NOPAT Margin		 9.93% 7.16% 0.27% 4.87% 2.40% -0.62%
Pre Tax Income Margin		 -68.79% -23.24% 44.62% 33.42% 5.85% 0.82%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 140.06% 172.98% -1,332.62%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 140.06% 174.45% -1,375.69%

Quarterly Metrics And Ratios for Cellebrite DI

No quarterly metrics and ratios for Cellebrite DI are available.

Frequently Asked Questions About Cellebrite DI's Financials

When does Cellebrite DI's fiscal year end?

According to the most recent income statement we have on file, Cellebrite DI's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Cellebrite DI's net income changed over the last 5 years?

Cellebrite DI's net income appears to be on an upward trend, with a most recent value of -$283.01 million in 2024, rising from -$1.88 million in 2019. The previous period was -$81.10 million in 2023. View Cellebrite DI's forecast to see where analysts expect Cellebrite DI to go next.

What is Cellebrite DI's operating income?
Cellebrite DI's total operating income in 2024 was $56.91 million, based on the following breakdown:
  • Total Gross Profit: $338.61 million
  • Total Operating Expenses: $281.70 million
How has Cellebrite DI revenue changed over the last 5 years?

Over the last 5 years, Cellebrite DI's total revenue changed from $171.85 million in 2019 to $401.20 million in 2024, a change of 133.5%.

How much debt does Cellebrite DI have?

Cellebrite DI's total liabilities were at $354.55 million at the end of 2024, a 28.9% decrease from 2023, and a 77.8% increase since 2020.

How much cash does Cellebrite DI have?

In the past 4 years, Cellebrite DI's cash and equivalents has ranged from $87.65 million in 2022 to $191.66 million in 2024, and is currently $191.66 million as of their latest financial filing in 2024.

How has Cellebrite DI's book value per share changed over the last 5 years?

Over the last 5 years, Cellebrite DI's book value per share changed from 0.00 in 2019 to 1.60 in 2024, a change of 160.4%.


Related Companies

This page (NASDAQ:CLBT) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Paradigm Press | Sponsored
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsored
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...
Colonial Metals | Sponsored